Efficacy of PD-1 blockade therapy and T cell immunity in lung cancer patients
Immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1) or PD-1 ligand-1 (PD-L1) have brought paradigm shift in lung cancer treatment. The median overall survival of patients with advanced non-small cell lung cancer treated with former standard platinum doublet cytocidal therapy...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-01-01
|
| Series: | Immunological Medicine |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/25785826.2019.1710427 |